Frontlight ResearchEarly access
CompletedNo phase
Melatonin for Knee Osteoarthritis Patients
Key facts
- Who runs it
- Xiangya Hospital of Central South University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 340 people enrolled
- Started
- 2 Nov 2023
- Ended
- 24 Sept 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Melatonin
- Placebo
- Record updated
- 20 November 2025
Who can take part
- Age
- 40 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Age between 40 and 80 years
- Knee OA according to the American College of Rheumatology (ACR) clinical criteria
- Knee pain lasting 3 months or longer and a score of 7 or greater on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale (standardized to range from 0-20)
- Kellgren-Lawrence (KL) grade 2 or 3
- Willing and able to provide written informed consent
Who cannot take part
- Any use of anti-depressive/psychotropic drugs
- History of injections of corticosteroids in the past three months or hyaluronic acid in the past 6 months in the index knee
- History of arthroscopy or open surgery in the index knee in the past 12 months
- History of a knee replacement in the index knee or planning to receive such a procedure within 3 months
- History of a severe injury in the index knee
- Pain in the index knee caused by inflammatory, autoimmune, neoplastic diseases or other diseases
- Severe cardiopulmonary diseases
- Uncontrolled hypertension or diabetes mellitus
- Diagnosis of malignant tumors
- Allergic to melatonin or its preparation
- Abnormal liver or kidney functions, as defined by alanine transaminase or aspartate aminotransferase >two times the upper limit of normal, or blood urea nitrogen or serum creatinine >two times the upper limit of normal
- Any use of NSAIDs or other analgesics in the past two weeks
- Pregnant or contemplating pregnancy or breastfeeding
- Any use of melatonin supplement before enrollment within 30 days
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
By recruiting knee osteoarthritis patients and treating them with melatonin, this study aims to determine the efficacy and safety of melatonin in alleviating pain in this patient population.
The 2 groups in the trial
- Oral melatonin supplementationTreatment being tested
Participants in the intervention arm will receive one 3 mg melatonin tablet every night before going to bed
Treatment: Melatonin
- PlaceboPlacebo, for comparison
The control group will receive an identical-looking inert placebo tablet every night before going to bed
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Melatonin for Pain Relief in Knee Osteoarthritis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
- Record updated
- 20 November 2025